Thalamocortical Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome

丘脑皮质反应性神经刺激治疗 Lennox-Gastaut 综合征

基本信息

  • 批准号:
    10414867
  • 负责人:
  • 金额:
    $ 259.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-06-01 至 2026-05-31
  • 项目状态:
    未结题

项目摘要

Project Summary / Abstract Lennox-Gastaut Syndrome (LGS) is a devastating form of childhood onset epilepsy with cognitive dysfunction and very frequent generalized onset seizures (GOS) often leading to injury. Driven by the lack of effective therapies and the demonstrated safety and efficacy of brain-responsive stimulation for medically intractable focal onset seizures (FOS), this study will test whether brain-responsive neurostimulation of thalamocortical networks (RNS-TCN) is a feasible strategy to treat LGS. Specifically, the project aims to: (1) acquire preliminary evidence for safety and efficacy in treating GOS of LGS with RNS-TCN; (2) create an interactive therapy-decision support system based on patient-specific computational network models and machine learning to identify optimal lead placement and stimulation parameters. Using the RNS® System, which is FDA approved for FOS, an early feasibility IDE study will be conducted at 6 epilepsy centers in 20 patients with LGS and medically intractable GOS. The patients will be enrolled in two cohorts of 10, with safety and efficacy milestones in the first cohort governing the enrollment of the second cohort. Patients will have two depth leads placed bilaterally in the centromedian nucleus of the thalamus and two subdural strip leads placed bilaterally on the medial prefrontal cortex. These targets are selected because they are implicated in the onset and spread of GOS in LGS. Leads will be located within each target such that stimulation maximally engages the thalamocortical network, guided by finite-element biophysical models created from structural magnetic resonance imaging and diffusion weighted imaging. The finite-element biophysical models will also be used to identify the initial RNS-TCN stimulation pathway and current amplitude. During the blinded evaluation period patients will be randomized to receive either high-frequency short burst (HFSB) or low-frequency long burst (LFLB) RNS-TCN, then enter a washout period before crossing over to receive the other treatment condition. During the open label period stimulation parameters can be modified at the discretion of the physician. Parameter adjustments will be informed by using a Bayesian optimization model developed for specifically for each patient. All clinical and electrophysiological data collected during the study will be used to identify a biomarker of clinical response; if found, these will aid future epilepsy research and clinical practice. If safety is favorable and there is preliminary evidence for efficacy, then this early experience will inform the design of a future larger feasibility study. In addition to treating a population in need, this project engages in fundamental discovery of biomarkers in generalized network epilepsies, and develops novel automated therapy selection policies that have the potential to improve the lives of patients with LGS and other seizure disorders.
项目摘要/摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARTHA J MORRELL其他文献

MARTHA J MORRELL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARTHA J MORRELL', 18)}}的其他基金

Thalamocortical Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome
丘脑皮质反应性神经刺激治疗 Lennox-Gastaut 综合征
  • 批准号:
    10615330
  • 财政年份:
    2021
  • 资助金额:
    $ 259.68万
  • 项目类别:
Thalamocortical Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome
丘脑皮质反应性神经刺激治疗 Lennox-Gastaut 综合征
  • 批准号:
    9958791
  • 财政年份:
    2021
  • 资助金额:
    $ 259.68万
  • 项目类别:
Thalamocortical Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome
丘脑皮质反应性神经刺激治疗 Lennox-Gastaut 综合征
  • 批准号:
    10674542
  • 财政年份:
    2021
  • 资助金额:
    $ 259.68万
  • 项目类别:
BONE HEALTH IN EPILEPSY
癫痫症的骨骼健康
  • 批准号:
    7205896
  • 财政年份:
    2005
  • 资助金额:
    $ 259.68万
  • 项目类别:
Bone Health in Epilepsy
癫痫症的骨骼健康
  • 批准号:
    7045009
  • 财政年份:
    2003
  • 资助金额:
    $ 259.68万
  • 项目类别:
Reproductive Function in Women with Bipolar Disorders
双相情感障碍女性的生殖功能
  • 批准号:
    7045027
  • 财政年份:
    2003
  • 资助金额:
    $ 259.68万
  • 项目类别:
EFFECTS OF ANTIEPILEPTIC DRUGS ON BONE TURNOVER AND MASS
抗癫痫药物对骨转换和质量的影响
  • 批准号:
    6567729
  • 财政年份:
    2001
  • 资助金额:
    $ 259.68万
  • 项目类别:
EFFECTS OF ANTIEPILEPTIC DRUGS ON BONE TURNOVER AND MASS
抗癫痫药物对骨转换和质量的影响
  • 批准号:
    6468469
  • 财政年份:
    2000
  • 资助金额:
    $ 259.68万
  • 项目类别:
HYPOTHALAMIC-PITUITARY-OVARIAN AXIS IN WOMEN WITH EPILEPSY
女性癫痫患者的下丘脑-垂体-卵巢轴
  • 批准号:
    6115032
  • 财政年份:
    1998
  • 资助金额:
    $ 259.68万
  • 项目类别:
ANALYSIS OF BONE HEALTH IN AED EXPOSED WOMEN WITH EPILEPSY
暴露于 AED 的癫痫女性的骨骼健康分析
  • 批准号:
    6115081
  • 财政年份:
    1998
  • 资助金额:
    $ 259.68万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 259.68万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 259.68万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 259.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 259.68万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 259.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 259.68万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 259.68万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 259.68万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 259.68万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 259.68万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了